Levels Dx, a diagnostics company focused on improving early detection of liver cancer, announced the successful close of its latest investment round. The new funding will support a clinical validation study in 300 patients, a critical step in the development of the company’s early-stage liver cancer test.
Liver cancer is often diagnosed at advanced stages, significantly limiting treatment options and survival rates. Levels Dx is developing a novel diagnostic approach aimed at identifying the disease earlier, when intervention can have the greatest impact on patient outcomes.
The upcoming validation study will evaluate the performance of the Levels Dx test across a diverse cohort of 300 patients, generating robust clinical evidence to support future regulatory and commercialization efforts. This study will utilize the latest proteomics methods in collaboration with SomaLogic, Seer and Quantall.
“This investment enables a major milestone for Levels Dx,” said Coen Breedveldof Levels Dx. “By validating our test in a large patient population, we are moving closer to delivering a much-needed solution for the early detection of liver cancer, where current screening options remain limited and imperfect.”
The round was supported by current investors and 3 new business angels among which one with a background in diagnostics, reflecting growing confidence in Levels Dx’s scientific approach and its potential to address a significant unmet clinical need.
Levels Dx plans to initiate the validation study in beginning of 2026 with results expected to inform subsequent development stages.
About Levels Dx
Levels Dx is a privately helddiagnostics company dedicated to transforming cancer care through earlier and more accurate detection. The company is focused on developing innovative tests for liver cancer, with the goal of improving survival and quality of life for patients worldwide.
For more information, visit www.levels.bio.
